Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Tremfya’s approval could signal new era in PsA

Janssen, a subsidiary of Johnson and Johnson (J&J), recently announced that Tremfya (guselkumab) received Food and Drug Administration (FDA) approval for patients with active psoriatic arthritis (PsA). Despite being launched in a fairly mature market, if J&J is able to contract aggressively with pharmacy benefit managers, leading data and analytics company GlobalData expects that Tremfya […]
Read more

Giving in to governmental pressure and approving sub-par vaccine may dissuade further innovation, says GlobalData

There are indications that some companies may be expediting the approval of COVID-19 vaccines, sometimes with subpar effectiveness, in response to pressure from governmental organizations. The approval of such vaccines may display short-term benefits, however, it will dissuade other companies and institutes from developing more effective vaccines if a significant proportion of the population has […]
Read more

Prioritized rollout required for COVID-19 vaccine to achieve 75% population vaccinated for herd immunity to be effective, says GlobalData

As a vaccine product passes through clinical development, manufacturers will have to ensure that they are taking the required steps to ramp up production, as there is unprecedented global demand. The quick manufacture and distribution of effective vaccine products are vital, as a slow or botched rollout may lead to global unrest due to the […]
Read more

Truvada likely to be preferred HIV prevention drug despite cabotegravir’s superiority

Following the results of a Phase IIb/III trial that showed GSK’s investigational HIV prevention drug cabotegravir had superior efficacy over Gilead’s Truvada; Arafa Salam, PhD, Infectious Diseases Analyst at GlobalData, a leading data and analytics, company offers her view: “Although cabotegravir may be more effective than Truvada, cabotegravir has potential high costs. Moreover, there are […]
Read more

India’s first indigenous biologic, Biocon’s ALZUMAb gets approval for COVID-19 treatment, says GlobalData

Following the news that India-based biopharma company Biocon’s plaque psoriasis drug itolizumab (ALZUMAb) has secured approval from the Drugs Controller General of India (DCGI) for emergency use in COVID-19 patients; Nag Madhavi, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “ALZUMAb is a novel humanized anti-CD6 monoclonal antibody, which was […]
Read more

Eli Lilly’s and Regeneron’s COVID-19 mAbs spark interest as monotherapies along with potential as cocktails for treatment and post-exposure prevention, says GlobalData

COVID-19 research and development (R&D) has started to see the first set of novel drug candidates enter clinical trials by way of monoclonal antibodies (mAbs). Experts interviewed by GlobalData see potential in these but are cautious that the cocktail strategy may not pan out better than treating with a single mAb, according to reporting from […]
Read more

Emerging technologies highly impacting management of COVID-19 outbreak

COVID-19 has had a catalytic effect on emerging technologies and has pushed several technologies into the forefront of methods to manage the pandemic. This is likely to be a watershed event and it is expected that these new technologies will continue to be used as tools to handle any future pandemics or crises, says GlobalData, a leading data and analytics company. Health agencies and governments are […]
Read more

Significant unmet needs remain in idiopathic pulmonary fibrosis despite recent advancements

Despite recent advances in idiopathic pulmonary fibrosis (IPF), significant unmet needs remain including increased earlier diagnosis, improved drug safety and efficacy, improvement in patient quality of life and treatments for patients with severe disease, according to GlobalData, a leading data and analytics company. Tiffany Chan, Immunology Analyst at GlobalData, explains: “There are a number of […]
Read more

COVID-19 disruption of clinical trials is in decline, says GlobalData

After three months of increasing trial disruptions, the number of disrupted trials began to fall between June and July. Most disruption was caused by the suspension of enrollment, followed by slow enrollment, and delayed initiation, says GlobalData, a leading data and analytics company. Brooke Wilson, Associate Director, Trials Intelligence at GlobalData, comments: “Although the total […]
Read more

Takeda continues post-Shire selloff to the benefit of Korean biopharma Celltrion, says GlobalData

South Korea-based bio/pharma company Celltrion has recently agreed to acquire a portfolio of 18 prescription pharmaceutical products and over-the-counter medicines across the Asia-Pacific (APAC) region for US$278.3m from Japan-based drug giant Takeda. This acquisition by Celltrion is part of Takeda’s massive divestment program to help release it from its crippling debt from its recent US$62bn […]
Read more

As Trump and Biden push to ‘Buy American’, $354m Government award to manufacture COVID-19 medicines in US raises suitability questions, says GlobalData

The US Federal Government’s Biomedical Advanced Research and Development Authority (BARDA) award of $354m to Phlow Corporation for the manufacture of COVID-19 medicines and other essential drugs has been touted by the Trump Administration as bringing pharmaceutical manufacturing back to the US. However, it is questionable why the $354m funding was awarded, seemingly without competition, […]
Read more

Cipla continues to expand focus on therapy areas of promising growth through deals, says GlobalData

India-based Cipla has recently entered into a partnership with Boehringer Ingelheim (BI) India Pvt. Ltd. to co-market three new oral anti-diabetics drugs in India, mainly sodium glucose co-transporter-2 (SGLT2) inhibitor Oboravo (empagliflozin), and related combination therapies – Oboravo Met (empagliflozin + metformin) and Tiptengio (empagliflozin + linagliptin). With this, along with recent agreements in the […]
Read more
1 … 86 87 88 89 90 … 110